Key Quantitative Figures
- Maximum transaction value: ₹630 crore for financial year 2026-27
- Breakdown: ₹600 crore for purchase of products, goods, raw materials, active pharmaceutical ingredients, stock-in-trade; ₹30 crore for business support services and recovery of cost
- Previous year transactions (FY 2025-26): ₹370 crore for purchase of vaccines
- Current year transactions (April-September 2026): ₹230 crore already transacted
- Value as percentage of company's annual consolidated turnover: 17%
- Value as percentage of related party's annual consolidated turnover: 1%
Dates and Timeline
- Cut-off date for shareholders: Friday, 13th November 2026
- E-voting commencement: Wednesday, 18th November 2026 at 9:00 AM IST
- E-voting conclusion: Thursday, 17th December 2026 at 5:00 PM IST
- Results announcement: On or before Saturday, 19th December 2026 by 5:00 PM IST
- Board meeting date: 3rd November 2026
Parties Involved
- Related Party: GSK Biological S.A. (Belgium)
- Scrutinizer: P.N. Parikh (FCS 327 and CP 1228) and Jigyasa Ved (FCS 6488 and CP 6018) of Parikh & Associates
- Registrar and Share Transfer Agent: KFin Technologies Limited
- Depositories: NSDL and CDSL
- Stock Exchanges: BSE Limited and National Stock Exchange of India Limited
Purpose and Rationale
The transactions involve purchase of products, goods, raw materials, active pharmaceutical ingredients, stock-in-trade, business support services and recovery of cost from GSK Biological S.A. (Belgium) in the ordinary course of business. GSK Biological S.A. is the manufacturing hub for vaccine production for the GSK Group globally, supplying patented vaccines to over 160 countries. The arrangement enables the Company to access high-quality pharmaceutical vaccines from GSK's global manufacturing facilities operating under stringent quality standards and regulatory compliance frameworks.
Approval Process
- Audit Committee granted omnibus approval for all transactions for FY 2026-27 at its meeting held in February 2026
- Independent Directors of Audit Committee reviewed and approved proposed transactions at meeting held on 3rd November 2026
- Board of Directors approved and recommended the transactions to shareholders at meeting held on 3rd November 2026
- Shareholder approval sought through postal ballot with e-voting facility
Financial Performance of Related Party
GSK Biological S.A. (Belgium) financials for calendar year 2025:
- Turnover: £6,469,383,000
- Profit After Tax: £2,379,294,000
- Net Worth: £8,674,902,000
Voting Instructions
- Individual shareholders holding securities in demat mode can vote through NSDL or CDSL platforms
- Shareholders holding physical shares and non-individual shareholders can vote through KFin Technologies Limited platform
- Corporate/Institutional shareholders must email scanned copy of Board Resolution to Scrutinizer
- Once vote is cast, it cannot be changed
Additional Information
- The Company has not breached material threshold limits for RPTs with GSK Biological S.A. as on the date of this Notice
- None of the Directors and/or Key Managerial Personnel(s) of the Company and/or their respective relatives are concerned or interested in the Resolution
- Related parties as defined under Listing Regulations shall not vote to approve the resolution